The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis.

Kongju WuMing YiShuang QinQian ChuXinhua ZhengKongming Wu

Published in: Experimental hematology & oncology (2019)

Combination treatment of α-PD-1 and α-CTLA-4 is a feasible strategy with enhanced efficacy and acceptable adverse event. Moreover, for some low PD-L1 expression patients, α-CTLA-4 might decrease the risk of resistance to α-PD-1 and demonstrate the synergistic anti-tumor effect.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
emergency department
cancer therapy
electronic health record
adverse drug